Mogamulizumab‐associated rash – Case series and review of the literature.

Summary: Mogamulizumab, a monoclonal antibody directed against CC chemokine receptor 4, is approved as a second‐line treatment of mycosis fungoides and Sézary syndrome. One of the most common side effects is mogamulizumab‐associated rash (MAR), which can present in a variety of clinical and histological types. Clinically, it can be difficult to differentiate between MAR and progression of the underlying disease, so histological examination is crucial for clinicopathological correlation. Current data analyses suggest that MAR is more common in patients with Sézary syndrome and is associated with a significantly better response to treatment, making the distinction from disease progression particularly important. The management of MAR depends on its severity, and therapy may need to be paused. This article presents three cases from our clinic and reviews the current literature on MAR. It emphasizes the importance of understanding MAR in the management of patients with cutaneous lymphomas. [ABSTRACT FROM AUTHOR]